세계 칸디다증 치료제 시장

Global Candidiasis Drugs Market to Reach US$5.2 Billion by 2030

The global market for Candidiasis Drugs estimated at US$4.3 Billion in the year 2023, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Azoles Drug Class, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Echinocandins Drug Class segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 3.0% CAGR

The Candidiasis Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$845.5 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Candidiasis Drugs Market - Key Trends and Drivers Summarized

Candidiasis, commonly known as yeast infection, is a fungal infection caused by Candida species, with Candida albicans being the most prevalent. These infections can range from superficial, such as oral thrush and vaginal yeast infections, to systemic and potentially life-threatening conditions, particularly in immunocompromised individuals. The candidiasis drugs market encompasses a variety of antifungal medications, including azoles (like fluconazole), echinocandins, and polyenes (such as amphotericin B). The treatment landscape has evolved significantly over the years with the introduction of new drug formulations and delivery methods that enhance efficacy and reduce side effects. Additionally, the growing awareness about fungal infections and the importance of early diagnosis have spurred the demand for effective candidiasis treatments.

The candidiasis drugs market has witnessed notable trends that are shaping its growth trajectory. One major trend is the increasing incidence of drug-resistant Candida strains, which has necessitated the development of new antifungal agents and combination therapies. Researchers are focusing on novel mechanisms of action to outpace the resistance. Additionally, advancements in biotechnology and genomics are facilitating the identification of new drug targets and the development of more effective treatments. There is also a growing trend towards personalized medicine, where treatments are tailored based on individual genetic profiles and specific characteristics of the fungal infection. Moreover, the integration of digital health technologies, such as telemedicine and mobile health apps, is improving patient access to treatment and adherence to medication regimens.

The growth in the candidiasis drugs market is driven by several factors. Technological advancements in drug development and delivery systems are enabling more efficient and targeted treatments, thus expanding the market. The rising prevalence of candidiasis, particularly among the aging population and those with weakened immune systems, such as HIV patients and cancer patients undergoing chemotherapy, is a significant driver. Additionally, increasing awareness and educational initiatives about fungal infections are prompting early diagnosis and treatment, thereby boosting market demand. Consumer behavior is also shifting towards seeking medical advice and over-the-counter treatments for recurrent infections, contributing to market growth. Furthermore, strong investment in research and development by pharmaceutical companies, along with supportive regulatory frameworks for fast-track approvals of antifungal drugs, is fostering innovation and expansion in the candidiasis drugs market.

Select Competitors (Total 86 Featured) -

• AdvaCare Pharma
• Astellas Pharma Inc
• Atom Pharma
• Cadila Pharmaceuticals Ltd.
• F2G Ltd
• Gilead Sciences, Inc
• GlaxoSmithKline (GSK Plc)
• Matinas BioPharma Holdings, Inc
• Melinta Therapeutics, Inc.
• Merck & Co., Inc
• Pfizer Inc
• Pulmocide Ltd
• SCYNEXIS, Inc.
• Viatris
• Xellia Pharmaceuticals;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Candidiasis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Innovative Antifungal Therapies Propel Growth in Candidiasis Drugs Market
  • Increasing Incidence of Drug-Resistant Strains Expands Addressable Market Opportunity
  • Advancements in Biotechnology and Genomics Strengthen Business Case for Novel Candidiasis Treatments
  • Rising Prevalence of Immunocompromised Conditions Spurs Demand for Effective Candidiasis Medications
  • Telemedicine and Mobile Health Apps Accelerate Demand for Convenient Candidiasis Medications
  • Growing Awareness and Early Diagnosis Throw the Spotlight on Candidiasis Drugs Market
  • Educational Initiatives Propel Growth by Promoting Early Detection and Treatment
  • Focus on Reducing Side Effects Enhances the Business Case for New Antifungal Medications
  • Evolving Drug Delivery Systems Generate Opportunities in the Candidiasis Drugs Market
  • Increasing Healthcare Expenditure Sustains Growth in Demand for Advanced Candidiasis Treatments
  • Innovations in Pharmacogenomics Strengthen Market Position of Personalized Candidiasis Drugs
  • Advancements in Combination Therapies Drive Adoption and Market Growth
  • Rise in Outpatient Treatment Models Propels Demand for Easily Accessible Candidiasis Medications
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Candidiasis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Echinocandins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Drugs Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• JAPAN
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• CHINA
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• EUROPE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• FRANCE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• GERMANY
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030

IV. COMPETITION